NCT07161843

Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)

Determine the Efficacy of Investigational Drug QRX-3 in Hospitalized Patients With Acute Tubular Necrosis Pattern of Acute Renal Failure

• Status: Not Yet Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 500 (estimated)
• Sponsor: Ebima Clifford Okundaye · Industry
• Sex: All
• Age: 10 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Use of QRX-3 in hospitalized patients with pediatric and adult patients with acute tubular necrosis renal failure

Conditions

• Acute Renal Failure (ARF)
• Acute Tubular Necrosis

Interventions

Type	Name	Description
DRUG	QRX-3	Combination of QRX-3 with standard therapy will be given to one arm in trial , another arm will receive placebo

Timeline

• Start date: 2026-06-30
• Primary completion: 2026-12-30
• Completion: 2027-02-01
• First posted: 2025-09-09
• Last updated: 2026-02-18

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study